Product Description
TRPM8 antagnonist (peipheral neuropathic pain); MT-8554 (Sourced from: https://www.mt-pharma.co.jp/e/develop/pipeline.html)
Mechanisms of Action: TRPM8 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Migraine Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| K-304 P001 | P2 |
Recruiting |
Migraine Disorders |
2025-12-01 |